Larimar Therapeutics, Inc. (LRMR) Misses Q1 EPS by 3c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Abivax reports Phase 3 maintenance trial results for obefazimod
• Bernstein SocGen on UnitedHealth Group (UNH): 'Expecting a strong 2Q driven by MA and potential for guidance raise'